Onconetix, Inc. Files S-1/A Amendment No. 3
Ticker: ONCO · Form: S-1/A · Filed: 2024-12-11T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, s-1/a, ipo-process
TL;DR
Onconetix (ONCO?) filed S-1/A #3. Public offering progress.
AI Summary
Onconetix, Inc. (formerly Blue Water Biotech, Inc.) filed an S-1/A amendment on December 11, 2024, for its registration statement. The company, incorporated in Delaware and based in Cincinnati, Ohio, is in the pharmaceutical preparations industry (SIC 2834). This filing is Amendment No. 3 to its Form S-1, with SEC file number 333-282958.
Why It Matters
This filing indicates Onconetix, Inc. is moving forward with its public offering process, which could lead to new capital for its operations and potential market impact.
Risk Assessment
Risk Level: medium — As a company undergoing a public offering, there are inherent risks associated with market reception and execution of their business plan.
Key Numbers
- 3 — Amendment Number (This is the third amendment to the S-1 registration statement.)
- 333-282958 — SEC File Number (Identifies this specific registration filing with the SEC.)
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former company name
- December 11, 2024 (date) — Filing date
- 333-282958 (other) — SEC File Number
- Karina M. Fedasz (person) — Interim Chief Financial Officer
FAQ
What is the purpose of this S-1/A filing?
This filing, Amendment No. 3 to Form S-1, is part of the registration process for Onconetix, Inc. to offer its securities to the public.
When was this amendment filed?
The amendment was filed with the SEC on December 11, 2024.
What was Onconetix, Inc. formerly known as?
Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and prior to that, Blue Water Vaccines Inc.
Where is Onconetix, Inc. headquartered?
Onconetix, Inc. is headquartered at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 2,082 words · 8 min read · ~7 pages · Grade level 8.4 · Accepted 2024-12-11 17:11:07
Filing Documents
- ea0224477-s1a3_onconetix.htm (S-1/A) — 70KB
- ea022447701ex10-45_onconetix.htm (EX-10.45) — 499KB
- ea022447701ex10-46_onconetix.htm (EX-10.46) — 142KB
- 0001213900-24-107952.txt ( ) — 712KB
Exhibits and Financial Statement
Item 16. Exhibits and Financial Statement Schedules. Incorporated by Reference Exhibit No. Description Form Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on February 23, 2022. 8-K 3.1 February 24, 2022 3.2 Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation 8-K 3.1 April 24, 2023 3.3 Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation. 8-K 3.1 December 21, 2023 3.4 Fourth Amended and Restated Bylaws of the Company. 8-K 3.2 December 21, 2023 3.5 Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024. 8-K 3.1 September 20, 2024 3.6 Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024. 8-K 3.1 September 24, 2024 4.1 Specimen Common Stock Certificate. S-1 4.1 October 8, 2021 4.2 Description of Registered Securities. 10-K 4.2 April 11, 2024 4.3 Form of Inducement PIO. 8-K 4.1 July 11, 2024 4.4 Form of Warrant. 8-K 4.1 October 3, 2024 4.5 Certification of Designation of Series C Preferred Stock. 8-K 3.1 October 3, 2024 5.1** Opinion of Ellenoff Grossman & Schole LLP as to the legality of the securities being registered. 10.1 2019 Equity Incentive Plan. S-1 10.1 October 8, 2021 10.2 2022 Equity Incentive Plan. S-1/A 10.2 November 29, 2021 10.3 2019 Equity Incentive Plan Form of Stock Option Grant Agreement. S-1 10.3 October 8, 2021 10.4 2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee). S-1/A 10.4 January 6, 2022 10.5 2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant). S-1/A 10.5 January 6, 2022 10.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, Ohio, on December 11, 2024. ONCONETIX, INC. By: /s/ Karina M. Fedasz Name: Karina M. Fedasz Title: Interim Chief Financial Officer Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. Signature Title Date * Interim Chief Executive Officer December 11, 2024 Ralph Schiess (Principal Executive Officer) /s/ Karina M. Fedasz Interim Chief Financial Officer December 11, 2024 Karina M. Fedasz (Principal Financial and Accounting Officer) * Chairman of the Board and Director December 11, 2024 James Sapirstein * Director December 11, 2024 Thomas Meier * Director December 11, 2024 Timothy Ramdeen * Director December 11, 2024 Ajit Singh * Director December 11, 2024 Simon Tarsh * Pursuant to Power of Attorney By: /s/ Karina M. Fedasz Karina M. Fedasz Attorney-in-Fact II-4